Navigation Links
Common Supplement May Help Patients Fight Heart Failure
Date:5/27/2013

oted that earlier, smaller trials with Coenzyme Q10 have produced mixed results. "Some studies have shown no effect, while other studies have shown some improvement, but not nearly the impressive effects displayed in this trial," he said.

Coenzyme Q10 occurs naturally in the body. It functions as an electron carrier in cellular mitochondria (the cell's "powerhouse") to help convert food to energy. It also is a powerful antioxidant, and has become a popular over-the-counter dietary supplement.

CoQ10 levels are decreased in the heart muscle of patients with heart failure, with the deficiency becoming more pronounced as the severity of their condition worsens, Mortensen said in the news release.

In this study, 420 patients with moderate to severe heart failure were tracked during two years. About half received 100 milligrams of CoQ10 three times a day, while the other half received a placebo.

By the end of the study, 18 patients from the CoQ10 group had died versus 36 deaths in the placebo group. Major adverse cardiovascular events requiring hospitalization had taken place in 29 CoQ10 patients, compared with 55 patients in the placebo group.

"It seems to be the largest trial so far to look at it in a rigorous way, to see if Coenzyme Q10 therapy affects outcomes in heart failure," said Dr. Margaret Redfield, head of the circulatory failure research group at Mayo Clinic. "As far as outcome trials go, it's still a pretty small trial. We have to interpret it cautiously. But it did seem to show a decrease in heart failure related events."

The potential of Coenzyme Q10 to treat heart failure patients has been a story told for more than two decades, added Dr. Michael Givertz, medical director for heart transplant and mechanical circulatory support at Brigham and Women's Hospital, Boston, and an associate professor of medicine for Harvard Medical School.

Studies have shown that Coenzyme Q10 does no harm and produces no side effects, G
'/>"/>

Copyright©2012 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds
2. Personal Injury Law Firm Issues New Infographic Detailing a Potential Link Between Stevens Johnson Syndrome and Common Children’s Medicines
3. Researchers find common childhood asthma unconnected to allergens or inflammation
4. Depression common among children with temporal lobe epilepsy
5. Pain a Common Problem for People With COPD
6. Injury Law Firm Announces New Informative Graphic on Common Medicines That Have Allegedly Been Linked to Stevens Johnson Syndrome
7. Physical & emotional impairments common, often untreated in people with cancer
8. Nurse staffing ratios affect hospital readmissions for children with common conditions
9. ‘Moderation and Common Sense’ is the Key to Living Well, States New BioGirl Health Show
10. Diagnosis, treatment of common outpatient disorder adds $238 million a year in ER costs
11. At-Home Drug Errors Common for Kids With Cancer, Research Shows
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Common Supplement May Help Patients Fight Heart Failure
(Date:11/27/2014)... According to a recent report by ... break into the surgical robotics market may ... the MIS field dominated by Intuitive. These companies are ... robotics market by 2020. , “The MIS robotic ... CEO and President of iData. “System sales for the ...
(Date:11/27/2014)... Blood-borne pathogens raise the risk of spreading ... in place to counter this. However, it doesn’t seem ... with menstrual blood are taken as seriously. , ... way to handle tampons and menstrual pads while also ... , He then created a prototype of the Sani-M, ...
(Date:11/27/2014)... HealthDay Reporter , WEDNESDAY, Nov. 26, 2014 ... a second language, new research suggests. But anyone who tries ... brain boost, the small study finds. The brain ... Ping Li, co-director of the Center for Brain, Behavior and ... Li said, that "the brain networks of the more successful ...
(Date:11/27/2014)... In order to enable people to adapt to ... easy way to avoid touching a toilet seat and/or lid ... prototype of the patent-pending Toilet Tamer, a device that enables ... lid in a more sanitary manner. It avoids direct contact ... it promotes good hygiene and peace of mind. The portable ...
(Date:11/27/2014)... 27, 2014 Tylenol lawsuits ( http://www.tylenollawsuitcenter.com/ ... injured by the medication are continuing to move forward ... looking ahead to a status conference in December, Bernstein ... Order issued earlier this year, a conference in the ... 10:00 a.m. Items likely to be discussed at the ...
Breaking Medicine News(10 mins):Health News:U.S. Robotic Surgery Market Set to Diversify and Grow: Intuitive Surgical’s ‘da Vinci’ Robot Revenues to Increasingly Rely On Procedures and Services 2Health News:Some People May Be Pre-Wired to Be Bilingual 2Health News:Some People May Be Pre-Wired to Be Bilingual 3Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 3
... with manufacturing, unreliable delivery of the drug , , FRIDAY, ... the drug rotigotine help relieve restless legs syndrome (RLS), ... drugs -- which stimulate the body,s dopamine system -- ... and rotigotine is already used to treat Parkinson,s disease. ...
... Appeal Action, EXTON, Pa., May 30 Isolagen(TM), ... it received notice from the staff,of the American Stock ... plan of compliance did not demonstrate its ability,to regain ... Sections 1003 (a)(i)-(iii) of the AMEX Company Guide within ...
... The following is being issued,by the Federation of Clinical ... from 58 countries across the globe, What: FOCIS 2008 ... June 4-Monday, June 9, Where: Boston Marriott Copley Place, ... that improves patient care, Wednesday, June 4, 8:30 ...
... with a certain type of prostate cancer have been ... plus prednisone in an international trial led by Oregon ... The research involved men with androgen-independent prostate cancer that ... prostate and is not longer responding to hormonal therapies. ...
... 16-0, in Favor of Short-Term Treatment of ... 30 GlaxoSmithKline (NYSE: GSK ),today ... Drug Administration,s,Oncology Drugs Advisory Committee (ODAC) unanimously ... risk-benefit profile for,the short-term treatment of patients ...
... HILL, N.C., May 30 Creating an effective ... a new product,s introduction.,A product,s promotion relies heavily ... benchmark companies ensure that they create effective, cross-functional,teams ... a new product., The detailed report provides ...
Cached Medicine News:Health News:Rotigotine Skin Patch May Ease Restless Legs Symptoms 2Health News:Isolagen, Inc. Reports Receipt of Initiation of Delisting Proceedings Notice from Amex 2Health News:Isolagen, Inc. Reports Receipt of Initiation of Delisting Proceedings Notice from Amex 3Health News:World-Renowned Scientists to Lead Immunology Course 2Health News:World-Renowned Scientists to Lead Immunology Course 3Health News:World-Renowned Scientists to Lead Immunology Course 4Health News:OHSU Cancer Institute researchers find novel chemo drug helps treat prostate cancer 2Health News:PROMACTA(R) (eltrombopag) RECEIVES UNANIMOUS RECOMMENDATION BY FDA ADVISORY PANEL 2Health News:PROMACTA(R) (eltrombopag) RECEIVES UNANIMOUS RECOMMENDATION BY FDA ADVISORY PANEL 3Health News:PROMACTA(R) (eltrombopag) RECEIVES UNANIMOUS RECOMMENDATION BY FDA ADVISORY PANEL 4Health News:Managing Cross-Functional Teams for Pharmaceutical Product Commercialization Excellence 2
(Date:11/26/2014)... 2014  Cohen, Placitella & Roth, PC is ... purchased Nymox Pharmaceutical Corporation ("Nymox" or "Company") (NASDAQ: ... January 31, 2011 through November 2, 2014 ("Class ... of its officers and directors publically disseminated materially ... 10(b) and 20(a) of the Securities Exchange Act ...
(Date:11/26/2014)... 26, 2014  Over 100 million adults suffer from ... this pain daily. Chronic and acute pain dramatically impacts ... born to fulfill the need for non-surgical, interventional solutions ... On October 28th, a new pain management ... Maryland community.  This new facility boasts cutting ...
(Date:11/26/2014)... 2014 Zynerba Pharmaceuticals , Inc., a ... transdermal synthetic cannabinoid treatments, today announced that the company ... Conference 2014. The conference will be held December 2 ... New York . Zynerba,s Chairman and CEO, ... on Tuesday, December 2. To listen to ...
Breaking Medicine Technology:Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 2Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 3New Pain Management Center Opens in Cumberland, Md. 2Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2
Validated by decades of research and clinical experience, HFA is the accepted standard of care in glaucoma diagnosis and management. With HFA you can feel confident you're providing the best possible...
... Rapidlab 1200's speed and accuracy allow ... in a timely manner - something ... especially patients. In fact, the Rapidlab ... in just one minute. Its maintenance-free, ...
... challenges. One complete solution. , Increased requirements ... Staff turnover. These are just some of ... challenges that can impact the amount of ... , , You can't afford ...
Dornier Holmium Laser for Urological Procedures...
Medicine Products: